Literature DB >> 1730128

Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies.

J M Vose1, B C Kennedy, P J Bierman, A Kessinger, J O Armitage.   

Abstract

The study was made to evaluate the long-term physical and psychosocial changes after high-dose therapy and autologous bone marrow or peripheral stem transplantation for recurrent lymphoid malignancies. Patients who had undergone high dose therapy and autologous bone marrow or peripheral stem cell transplantation for recurrent lymphoid malignancies at least 1 year previously were contacted by phone interview regarding their status after the transplant. The patients' comments were confirmed by checking medical records when possible. Fifty patients who had undergone transplantation at the University of Nebraska Medical Center at least 1 year before the interview were available for interview and willing to answer questions. After transplant, many patients noticed temporary changes in their appearance, which usually returned to normal within 1 year. Few patients reported remarkable cardiovascular, gastrointestinal, or pulmonary changes after transplantation. However, up to one-third of the patients reported changes in sexual function or desire. The most common infectious problem after transplant was Herpes zoster, which occurred in 25% of the patients. Overall, the patients had a positive outlook after high-dose therapy and transplantation, with most being able to return to work and enjoy a normal life style. Ninety-six percent of the patients stated that they would be willing to undergo high-dose therapy and transplantation again under the same circumstances.

Entities:  

Mesh:

Year:  1992        PMID: 1730128     DOI: 10.1002/1097-0142(19920201)69:3<784::aid-cncr2820690328>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Early infections after autologous transplantation for haematological malignancies.

Authors:  I Schiødt; O J Bergmann; H E Johnsen; N E Hansen
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

2.  Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.

Authors:  Areej El-Jawahri; Yi-Bin Chen; Ruta Brazauskas; Naya He; Stephanie J Lee; Jennifer M Knight; Navneet Majhail; David Buchbinder; Raquel M Schears; Baldeep M Wirk; William A Wood; Ibrahim Ahmed; Mahmoud Aljurf; Jeff Szer; Sara M Beattie; Minoo Battiwalla; Christopher Dandoy; Miguel-Angel Diaz; Anita D'Souza; Cesar O Freytes; James Gajewski; Usama Gergis; Shahrukh K Hashmi; Ann Jakubowski; Rammurti T Kamble; Tamila Kindwall-Keller; Hilard M Lazarus; Adriana K Malone; David I Marks; Kenneth Meehan; Bipin N Savani; Richard F Olsson; David Rizzieri; Amir Steinberg; Dawn Speckhart; David Szwajcer; Helene Schoemans; Sachiko Seo; Celalettin Ustun; Yoshiko Atsuta; Jignesh Dalal; Carmem Sales-Bonfim; Nandita Khera; Theresa Hahn; Wael Saber
Journal:  Cancer       Date:  2017-01-19       Impact factor: 6.860

3.  Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies.

Authors:  Farah Sahoo; Joshua A Hill; Hu Xie; Wendy Leisenring; Jessica Yi; Sonia Goyal; Louise E Kimball; Ingi Lee; Sachiko Seo; Chris Davis; Stephen A Pergam; Mary E Flowers; Kai-Li Liaw; Leona Holmberg; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-28       Impact factor: 5.742

Review 4.  Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation.

Authors:  Neel S Bhatt
Journal:  Curr Hematol Malig Rep       Date:  2022-10-04       Impact factor: 4.213

5.  Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes.

Authors:  H Mawardi; S Elad; M E Correa; K Stevenson; S-B Woo; S Almazrooa; R Haddad; J H Antin; R Soiffer; N Treister
Journal:  Bone Marrow Transplant       Date:  2011-04-04       Impact factor: 5.483

6.  Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.

Authors:  L K Seymour; R D Dansey; W R Bezwoda
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

7.  Quality of life following bone marrow transplantation: findings from a multicentre study.

Authors:  M A Andrykowski; C B Greiner; E M Altmaier; T G Burish; J H Antin; R Gingrich; C McGarigle; P J Henslee-Downey
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

Review 8.  Oral complications and management strategies for patients undergoing cancer therapy.

Authors:  Hai Ming Wong
Journal:  ScientificWorldJournal       Date:  2014-01-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.